癌症研究
肿瘤微环境
免疫疗法
免疫原性细胞死亡
免疫系统
化学
重编程
树突状细胞
癌症免疫疗法
T细胞
转移
纳米载体
光热治疗
梅尔特克
髓样
肿瘤相关巨噬细胞
免疫学
联合疗法
癌症
抗原呈递
CD8型
抗原提呈细胞
甘露糖受体
医学
获得性免疫系统
癌细胞
细胞毒性T细胞
黑色素瘤
先天免疫系统
多西紫杉醇
细胞疗法
全身给药
免疫检查点
细胞
药理学
作者
Zang Xin,Liu Dezhi,Zhang Jingyi,Xuyuan Chao,Chen Xin,Yang Shengjie,Fang Yingying,L J Yan,Li Yinjuan,Qi Lu,Xinghe Wang
标识
DOI:10.1016/j.mtbio.2026.103086
摘要
In triple-negative breast cancer (TNBC), tumor-associated macrophages (TAMs) and tumor-infiltrating dendritic cells (TIDCs) often exhibit an immunosuppressive phenotype. This myeloid-dominant milieu reinforces an immune-cold state, promotes metastasis and contributes to immunotherapy resistance. In this study, we developed a mannose-functionalized graphene oxide nanocarrier (GO-EDM) with favorable biocompatibility and high NIR photothermal conversion efficiency. Docetaxel and vadimezan (DMXAA), a prototypical STING agonist, were co-loaded into GO-EDM to generate GO-EDM-DTX-Vad. In vitro, the nanocomposite promoted M2-to-M1 repolarization, thereby attenuating pro-tumor paracrine signaling from M2 macrophages and limiting TNBC cell proliferation, migration and invasion. Concomitantly, it promoted dendritic cell maturation and induced immunogenic cell death (ICD) in tumor cells, collectively enhancing antigen presentation and T-cell activation. In vivo, both intratumoral administration and systemic intravenous administration of GO-EDM-DTX-Vad effectively suppressed primary tumor growth. In a lung metastasis model, when combined with 808 nm NIR irradiation, the pulmonary metastatic burden was significantly reduced. Specifically, this treatment reduced the accumulation of M2 macrophages, MDSCs and Tregs within tumors, while promoting DC maturation and increasing intratumoral infiltration of M1 macrophages, CD8 + T cells and memory T cells. Taken together, GO-EDM-DTX-Vad leverages passive tumor accumulation and mannose receptor–guided dual targeting of TAMs and TIDCs to integrate DTX-based chemotherapy, STING-mediated immune activation and mild NIR photothermal therapy. This integrated chemo–photothermal–immunotherapeutic design couples direct tumor cell killing with myeloid reprogramming and immune activation, offering a unified strategy for metastatic TNBC. (A) Synthesis and stimuli-responsive drug release of GO-EDM-DTX-Vad. (B) Schematic illustration of GO-EDM-DTX-Vad for precision drug delivery, immunosuppressive tumor microenvironment reprogramming and cancer therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI